Reported Thursday, Pendopharm Partners With Ascendis Pharma For Exclusive Distribution of TransCon PTH In Canada
Reported Thursday, Pendopharm Partners With Ascendis Pharma For Exclusive Distribution of TransCon PTH In Canada
週四報道，Pendopharm與Ascendis Pharma合作，獨家分銷TransCon PTH在加拿大。
Under the terms of the agreement, Pendopharm is responsible for regulatory approval and commercialization of Ascendis' hypoparathyroidism treatment TransConTM PTH (palopegteriparatide) in Canada. Financial terms of the agreement are not disclosed.
根據協議，《TransConTm PTH》（palopegteriparatide）在加拿大的藥品監管批准和商業化責任屬於彭多費爾姆公司。協議的財務條款未披露。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。